Mostrar el registro sencillo del ítem

Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA-FLUO Trial

dc.rights.licenseopenen_US
dc.contributor.authorRASCOL, Olivier
dc.contributor.authorCOCHEN DE COCK, Valerie
dc.contributor.authorPAVY-LE TRAON, Anne
hal.structure.identifierInstitut des Maladies Neurodégénératives [Bordeaux] [IMN]
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorSAMIER FOUBERT, Alexandra
dc.contributor.authorTHALAMAS, Claire
dc.contributor.authorSOMMET, Agnes
dc.contributor.authorROUSSEAU, Vanessa
dc.contributor.authorPEREZ-LLORET, Santiago
dc.contributor.authorFABBRI, Margherita
dc.contributor.authorAZULAY, Jean-Philippe
dc.contributor.authorCORVOL, Jean-Christophe
dc.contributor.authorCOURATIER, Philippe
dc.contributor.authorDAMIER, Philippe
dc.contributor.authorDEFEBVRE, Luc
dc.contributor.authorDURIF, Franck
dc.contributor.authorGENY, Christian
dc.contributor.authorHOUETO, Jean-Luc
dc.contributor.authorREMY, Philippe
dc.contributor.authorTRANCHANT, Christine
dc.contributor.authorVERIN, Marc
hal.structure.identifierInstitut des Maladies Neurodégénératives [Bordeaux] [IMN]
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorTISON, Francois
hal.structure.identifierInstitut des Maladies Neurodégénératives [Bordeaux] [IMN]
dc.contributor.authorMEISSNER, Wassilios
IDREF: 113664761
dc.contributor.authorGROUP, Msa-Fluo Study
dc.date.accessioned2021-06-30T09:54:24Z
dc.date.available2021-06-30T09:54:24Z
dc.date.issued2021-04-01
dc.identifier.issn0885-3185en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/94935
dc.description.abstractEnBACKGROUND: There are no effective treatments for multiple system atrophy (MSA). OBJECTIVE: The objective of this study was to assess the efficacy and safety of the serotonin reuptake inhibitor fluoxetine (40 mg/d) for the symptomatic treatment of MSA. METHODS: This was a double-blind, parallel-group, placebo-controlled, randomized trial in patients with "probable" MSA. The primary outcome was the change from baseline to week 12 in the mean total score of the Unified MSA Rating Scale (UMSARS Parts I + II). Secondary outcomes included change from baseline to week 6 in total UMSARS, and change from baseline to week 12 in the Scales for Outcomes in Parkinson Disease-Autonomic Dysfunction, Beck Depression Inventory, and different domains of the MSA-Quality of Life Questionnaire. Exploratory outcomes included change from baseline to week 12 in the UMSARS Parts I and II separately and change from baseline to week 24 in the total UMSARS score. RESULTS: A total of 81 patients were randomly assigned, with no significant difference in the primary outcome (-2.13 units [95% confidence interval, CI, -4.55 to 0.29]; P = 0.08). There was a greater reduction on fluoxetine in the change from baseline to 12-week in UMSARS Part II (exploratory outcome: -1.41 units [95% CI, -2.84; 0.03]; p = 0.05) and in MSA-QoL emotional/social dimension (secondary outcome: -6.99 units [95% CI, -13.40; -0.56]; p < 0.03). A total of 5 deaths occurred (3 on fluoxetine and 2 on placebo). CONCLUSION: The MSA-FLUO failed to demonstrate fluoxetine superiority over placebo on the total UMSARS score, whereas trends in motor and emotional secondary/exploratory outcomes deserve further investigation. © 2021 International Parkinson and Movement Disorder Society.
dc.language.isoENen_US
dc.subject.enFluoxetine
dc.subject.enMultiple system atrophy
dc.subject.enClinical trial
dc.subject.enPlacebo
dc.subject.enSymptomatic treatment
dc.title.enFluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA-FLUO Trial
dc.typeArticle de revueen_US
dc.identifier.doi10.1002/mds.28569en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed33792958en_US
bordeaux.journalMovement Disordersen_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamSEPIAen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDMinistère des Solidarités et de la Santéen_US
hal.exportfalse
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=Movement%20Disorders&amp;rft.date=2021-04-01&amp;rft.eissn=0885-3185&amp;rft.issn=0885-3185&amp;rft.au=RASCOL,%20Olivier&amp;COCHEN%20DE%20COCK,%20Valerie&amp;PAVY-LE%20TRAON,%20Anne&amp;SAMIER%20FOUBERT,%20Alexandra&amp;THALAMAS,%20Claire&amp;rft.genre=article


Archivos en el ítem

ArchivosTamañoFormatoVer

No hay archivos asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem